Tirzepatide is a once-weekly subcutaneous injectable peptide engineered from the native GIP sequence, with agonist activity at both the GIP and GLP-1 receptors, and it has been approved for type 2 diabetes. The gene discussed is GIP; the disease is type 2 diabetes mellitus.